Advertisement

Archives of Gynecology and Obstetrics

, Volume 244, Issue 2, pp 113–122 | Cite as

CA 125 in normal tissues and carcinomas of the uterine cervix, endometrium and fallopian tube

II. Immunoradiometric determination in secretions, tissue extracts and serum
  • G. Crombach
  • A. Scharl
  • H. Würz
Originals

Summary

The study deals with the occurrence of cancer antigen 125 (CA 125) in the normal and neoplastic uterine cervix, endometrium and fallopian tube and its applicability as a tumour marker. CA 125 concentrations were measured in 52 secretion specimens, in cytosol fractions of 97 tissue biopsies and in serum from 47 women with nonmalignant disorders and from 334 patients with carcinomas. High quantities of CA 125 (780-454860 U/ml) were detected in cervical mucus, intra-uterine and tubal fluid, exceeding those in the corresponding serum samples by factors of up to 2000. CA 125 concentrations were 9–53 fold higher in cytosol fractions of normal and neoplastic glandular epithelia of the endocervix and endometrium than in those of cervical squamous epithelia and the cervical wall. Despite similarly high antigen concentrations in normal glandular epithelia and adenocarcinomas serum levels elevated to above 65 U/ml were only found in patients with malignant tumours. The positivity rates in serum increased with tumour extent and were 0–43% for primary and 63–79% for recurrent cervical, endometrial and tubal adenocarcinomas. During long-term follow-up, CA 125 serum concentrations were concordant with the clinical course in 10 out of 11 patients with progressive carcinomas. According to these results, the release of CA 125 into the peripheral blood is apparently dependent on the infiltrative growth and the mass of the tumour rather than on, the local tissue concentrations. The clinical use of CA 125 is limited to the detection of advanced adenocarcinomas of the Müllerian duct.

Key words

CA 125 Immunoradiometric assay Cervix uteri Endometrium Fallopian tube 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887Google Scholar
  2. 2.
    Crombach G, Würz H, Bolte A (1987) CA 125, ein Tumormarker für Adenokarzinome der Endozervix, des Endometriums und der Tube? Arch Gynecol Obstet 242:382–383Google Scholar
  3. 3.
    De Bruijn HWA, Beeck Calkoen-Carpay T van, Jager S, Duk JM, Aalders JG, Fleuren GJ (1986) The tumour marker CA 125 is a common constituent of normal cervical mucus. Am J Obstet Gynecol 154:1088–1091Google Scholar
  4. 4.
    De Bruijn HWA, Aalders JG, Kauer FM, Duk JM, Fleuren GJ (1987) The biodistribution of CA 125 in the female genital tract. In: Klapdor R (ed) New tumour markers and their monoclonal antibodies. Thieme, Stuttgart, p 334Google Scholar
  5. 5.
    Duk JM, Aalders JG, Fleuren GJ, Bruijn HWA de (1986) A useful marker in endometrial carcinoma. Am J Obstet Gynecol 155:1097–1102Google Scholar
  6. 6.
    Fuith LC, Daxenbichler G, Dapunt O (1987) CA 125 in the serum and tissue of patients with gynecological disease. Arch Gynecol, Obstet 241:157–164Google Scholar
  7. 7.
    Guidice LC, Jacobs AJ, Bell CE, Lippmann L (1986) Letter to the editor. Gynecol Oncol 25:256–258Google Scholar
  8. 8.
    Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB (1983) Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC 125. Int J Gynecol Pathol 2:275–285Google Scholar
  9. 9.
    Kaesemann H, Caffier H, Hoffmann FJ, Crombach G, Würz H, Kreienberg R, Möbus V, Schmidt-Rhode P, Sturm G (1986) Monoklonale Antikörper in Diagnostik und Verlaufskontrolle des Ovarialkarzinoms. CA 125 als Tumormarker. Klin Wochenschr 64:781–785Google Scholar
  10. 10.
    Lootsma-Miklosova E, Aalders JG, Willemse PHB, de Bruijn HWA (1987) Levels of CA 125 in patients with recurrent carcinoma of the fallopian tube. Eur J Obstet Gynecol Reprod Biol 24:231–235Google Scholar
  11. 11.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folinphenol reagent. J Biol Chem 193:265–275Google Scholar
  12. 12.
    Malkasian GD, Podratz KC, Stanhope CR, Ritts RE, Zurawski VR (1986) CA 125 in gynecologic practice. Am J Obstet Gynecol 155:515–518Google Scholar
  13. 13.
    Niloff JM, Klug T, Schaetzel E, Zurawski, VR, Knapp RC, Bast RC (1984) Evaluation of serum CA 125 in carcinomas of the fallopian tube, endometrium,: and endocervix. Am J Obstet Gynecol 148:1057–1058Google Scholar
  14. 14.
    Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR, Bast RC (1986) The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 155:56–60Google Scholar
  15. 15.
    Patsner B, Mann WJ, Cohen H, Loesch M (1988) Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol 158:399–402Google Scholar
  16. 16.
    Scharl A, Crombach G, Müsch H, Vierbuchen M, Bolte A (1989) Occurrence of CA 125 in normal tissues and carcinomas of the uterine cervix endometrium and fallopian tube. I: Immunohistochemical detection. Arch Gynecol Obstet 244:103–112Google Scholar
  17. 17.
    Schmidt-Rhode P, Schulz KD, Sturm G (1987) Tumour markers and endometrial cancer. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds) Endometrial cancer. Zuckschwerdt, MünchenGoogle Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • G. Crombach
    • 1
  • A. Scharl
    • 1
  • H. Würz
    • 1
  1. 1.Department of Obstetrics and GynaecologyUniversity of CologneFRG

Personalised recommendations